Mylenda Injection 1 mg/0.5 ml contains Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus in adults. This higher-strength formulation is typically prescribed for patients who require enhanced glycemic control after gradual dose escalation. It provides sustained blood glucose reduction with the convenience of once-weekly administration.

Semaglutide acts by mimicking the endogenous GLP-1 hormone, which plays a key role in glucose homeostasis. It increases glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and delays gastric emptying. These combined actions help lower fasting and postprandial plasma glucose levels while minimizing the risk of hypoglycemia when used without insulin or insulin secretagogues. In addition, semaglutide affects appetite regulation in the brain, leading to reduced food intake and clinically meaningful weight loss in many patients, an added benefit in the management of type 2 diabetes.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Mylenda Injection 1 mg is indicated as an adjunct to diet and exercise for:

• Management of type 2 diabetes mellitus in adult patients

• Patients requiring further improvement in glycemic control after lower doses

• Use as monotherapy or in combination with other antidiabetic medications, as prescribed by a healthcare professional

Dosage and Administration

Mylenda Injection is administered by subcutaneous injection. The 1 mg dose is usually introduced after patients have tolerated lower doses of semaglutide. It is given once weekly, on the same day each week, at any time of day, with or without meals.

The injection may be administered into the abdomen, thigh, or upper arm. Injection sites should be rotated to reduce the risk of local reactions. Dose adjustments and treatment duration should be determined by the treating physician based on clinical response and tolerability.

Key Benefits

• Strong and sustained reduction in blood glucose levels

• Once-weekly dosing for improved patient compliance

• Low risk of hypoglycemia when used alone

• Supports significant weight reduction

• Proven long-term efficacy in type 2 diabetes management

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Not intended for use in type 1 diabetes mellitus or diabetic ketoacidosis

• Use with caution in patients with a history of pancreatitis

• Contraindicated in patients with a personal or family history of medullary thyroid carcinoma

• Gastrointestinal adverse effects may occur, especially during dose escalation

• Regular monitoring of blood glucose and overall metabolic control is advised

Adverse Effects

Commonly reported adverse effects include:

• Nausea and vomiting

• Diarrhea or constipation

• Abdominal pain or discomfort

• Decreased appetite

• Injection site reactions

Most adverse effects are mild to moderate and tend to diminish with continued therapy.

Storage Conditions

Store Mylenda Injection in a refrigerator at 2°C–8°C. Do not freeze. Protect from light. Follow the manufacturer’s instructions regarding storage after first use. Keep out of reach of children.

Conclusion

Mylenda Injection 1 mg/0.5 ml (Semaglutide) is an effective once-weekly injectable therapy for adults with type 2 diabetes mellitus who require advanced glycemic control. Its multi-mechanistic action, convenience, and added benefit of weight reduction make it a valuable option for long-term diabetes management under medical supervision.